This article has been peer reviewed and accepted for publication. It is in production and has not been edited, so may differ from the final published form.
Intensive sex partying with GHB: Factors associated with using GHB for chemsex among Australian gay and bisexual men – Results from the Flux Study
Background: Gamma-hydroxybutyrate (GHB) use among gay and bisexual men (GBM) has increased in recent years. It is commonly cited as a sexual enhancement drug. There is, however, little evidence for factors associated with GHB use or the consequences of its use among GBM. Aim: We examine factors associated with GHB use, its relationship to sexual risk behaviour, and the contexts, consequences, and motivations for its use. Methods: The Following Lives Undergoing Change (Flux) study is an online prospective observational study of Australian GBM. At baseline, a total of 3190 GBM provided details about their use of GHB. We collected data on frequency, methods, pleasures and consequences for their drug use, alongside key demographic variables. Results: Mean age was 35.0 years. One in five men (19.5%) had a history of GHB use and 5.4% reported use within the previous six months, with 2.7% having used it monthly or more frequently. 14.7% had experienced drug overdose, which was more common among men who used GHB at least monthly. Being HIV-positive, having more gay friends, greater social engagement with gay men who use drugs, a greater number of sexual partners, group sex, and condomless anal intercourse with casual partners were independently associated with GHB use in the previous six months. Greater social engagement with gay men who use drugs and group sex were independently associated with at least monthly use. More frequent GHB use was independently associated with experiencing overdose among GHB users. Conclusion: Most men used GHB infrequently and often explicitly to enhance sexual experiences, often in the context of intensive sex partying. Men who used GHB frequently, were at greater risk of overdose and other negative health outcomes. GHB use should be considered alongside other drugs that have been implicated in sexual risk behaviour and HIV transmission. Harm reduction interventions need to consider the particular impact of frequent GHB use.
SH17146 Accepted 27 September 2017
© CSIRO 2017